ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial

Background

Recent research shows that a treatment called stereotactic body radiotherapy (SBRT) can help men with a specific type of prostate cancer that has spread to a few other areas. This study looked at whether adding a short course of hormone therapy (ADT) to SBRT could help patients live longer without their cancer getting worse.

Study Overview

The RADIOSA study was conducted in Milan, Italy, involving men diagnosed with prostate cancer that had returned after initial treatment. The study included 105 participants who were randomly assigned to receive either SBRT alone or SBRT combined with 6 months of hormone therapy. The main goal was to see how long patients could go without their cancer progressing.

Key Findings

After following the patients for about 31 months, those who received both SBRT and hormone therapy had a median progression-free survival of 32.2 months, compared to 15.1 months for those who only received SBRT. This means that the combination treatment significantly delayed cancer progression.

Safety and Side Effects

There were few side effects reported. Most were mild, and there were no treatment-related deaths. One patient experienced a serious side effect related to the hormone therapy, but overall, the treatments were well tolerated.

Conclusion

This study suggests that combining SBRT with hormone therapy can be more effective than SBRT alone for certain prostate cancer patients. It highlights the importance of personalized treatment plans and the need for further research to optimize these therapies.

Opportunities for Clinics and Patients

Clinics can use these findings to improve treatment strategies for prostate cancer patients. Setting clear goals based on measurable outcomes from this study can help in tailoring treatments to individual needs.

Implementing AI Solutions

To enhance patient management, clinics can explore AI tools that fit their specific needs. Starting with pilot projects and tracking results can help in understanding the real-world impact of these treatments.